Mirtazapin Orion (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Orion, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is available across European markets and is prescribed for major depressive disorder in adult patients, helping to improve mood, sleep and appetite.

GNH USA supplies Mirtazapin Orion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand continuously.

Mirtazapine is a NaSSA antidepressant that acts on noradrenergic and serotonergic pathways to treat depressive disorders.

Major depressive disorder: reduces depressive symptoms and improves mood, sleep and appetite in adult patients. Depressive disorder with anxiety: alleviates anxiety symptoms associated with depression. Depression with insomnia: promotes sleep onset and continuity, helping patients with depressive‑related insomnia.

Mirtazapine may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Somnolence

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Severe skin reactions such as Stevens‑Johnson syndrome - Suicidal thoughts or behavior, especially early in treatment

When prescribing mirtazapine, clinicians should consider several safety measures to minimize risk.

Assess hepatic function: evaluate liver impairment before initiating therapy Monitor for suicidal ideation: especially during the first weeks of treatment Check for hypersensitivity: discontinue if rash or angioedema develops Use caution in elderly patients: increased risk of sedation and falls Avoid abrupt discontinuation: taper dose under medical supervision Store at ambient temperature: keep in original container, protect from moisture and light

Mirtazapine can interact with other medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome - Other serotonergic antidepressants (SSRIs, SNRIs, tricyclics): increased serotonin syndrome risk - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels

Moderate Interactions (Monitor Closely): - Antihistamines: may enhance sedative effect - Benzodiazepines: increased central nervous system depression - Carbamazepine: may reduce mirtazapine concentrations